亿帆医药(002019.SZ)：注射用硫酸多黏菌素B获得药品注册证书

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) has received approval from the National Medical Products Administration for the injection of Polymyxin B sulfate, which is primarily used to treat severe infections caused by carbapenem-resistant Gram-negative bacteria in adult patients [1] Group 1: Company Information - Yifan Pharmaceutical's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable Polymyxin B sulfate on January 22, 2026 [1] - The approved drug is indicated for treating infections caused by sensitive strains of Pseudomonas aeruginosa, including meningitis and bacteremia [1]